Cytokinetics (CYTK) Net Cash Flow (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Net Cash Flow of $7.8 million for Q1 2026, up 137.13% year-over-year from $3.3 million in Q1 2025, and up 107.53% quarter-over-quarter from -$103.1 million in Q4 2025.
Cytokinetics (CYTK) Net Cash Flow (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Net Cash Flow for 17 consecutive years, with $7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 137.13% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $59.8 million (up 229.4% YoY), while the FY2025 annual figure was $31.1 million, up 269.37% from the prior year.
- Net Cash Flow rose to $7.8 million in Q1 2026 per CYTK's latest filing, from -$103.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $152.0 million in Q3 2025 and bottomed at -$143.1 million in Q3 2024.
- Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of $6.9 million in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow surged 1207.47% — and 2024, when it slumped 560.92%.
- Cytokinetics' Net Cash Flow stood at -$39.1 million in 2022, then soared by 134.19% to $13.4 million in 2023, then jumped by 257.08% to $47.7 million in 2024, then slumped by 316.31% to -$103.1 million in 2025, then jumped by 107.53% to $7.8 million in 2026.
- Business Quant data shows CYTK's Net Cash Flow at $7.8 million in Q1 2026, -$103.1 million in Q4 2025, and $152.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 126.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.06 Mn |
| Jun 30, 2026 | 126.06 Mn |
| Mar 31, 2026 | 7.76 Mn |
| Mar 31, 2026 | 7.76 Mn |
| Dec 31, 2025 | -103.13 Mn |
| Dec 31, 2025 | -103.13 Mn |
| Sep 30, 2025 | 151.98 Mn |
| Sep 30, 2025 | 151.98 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Dec 31, 2024 | 47.68 Mn |
| Dec 31, 2024 | 47.68 Mn |
| Sep 30, 2024 | -143.13 Mn |
| Sep 30, 2024 | -143.13 Mn |
| Jun 30, 2024 | 70.15 Mn |
| Jun 30, 2024 | 70.15 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Mar 31, 2024 | 6.93 Mn |